PLATFORM
Treatment Modalities with Universal Applicability
PLATFORM
Treatment Modalities with Universal Applicability
PLATFORM
Treatment Modalities with Universal Applicability
Platform
TRANSMAB®
Conventional antibodies cannot normally enter the brain due to physical barrier known as the blood-brain barrier (BBB).
TRANSMAB® platform transforms conventional antibodies into novel, next-generation BBB-penetrating antibodies by fusing multiple copies of de novo peptides selected from the TRANSPEP® library using our proprietary deep learning model.
TRANSMAB® antibodies are specifically designed to bind to the distinctive dense clustering patterns of transferrin receptors expressed on brain capillaries, enabling them to effectively penetrate throughout the brain parenchyma.
Platform
TRANSMAB®
Conventional antibodies cannot normally enter the brain due to physical barrier known as the blood-brain barrier (BBB).
TRANSMAB® platform transforms conventional antibodies into novel, next-generation BBB-penetrating antibodies by fusing multiple copies of de novo peptides selected from the TRANSPEP® library using our proprietary deep learning model.
TRANSMAB® antibodies are specifically designed to bind to the distinctive dense clustering patterns of transferrin receptors expressed on brain capillaries, enabling them to effectively penetrate throughout the brain parenchyma.
Platform
TRANSMAB®
Conventional antibodies cannot normally enter the brain due to physical barrier known as the blood-brain barrier (BBB).
TRANSMAB® platform transforms conventional antibodies into novel, next-generation BBB-penetrating antibodies by fusing multiple copies of de novo peptides selected from the TRANSPEP® library using our proprietary deep learning model.
TRANSMAB® antibodies are specifically designed to bind to the distinctive dense clustering patterns of transferrin receptors expressed on brain capillaries, enabling them to effectively penetrate throughout the brain parenchyma.
Library
TRANSPEP®
We harness the synergy of de novo design, structural biology, and directed evolution approaches to craft hypercompact and stable protein binders targeting the transferrin receptor.
TRANSPEP® library consists of de novo peptides with diverse affinities and properties for multivalent fusion with a conventional antibody, ensuring optimized avidity control.
Library
TRANSPEP®
We harness the synergy of de novo design, structural biology, and directed evolution approaches to craft hypercompact and stable protein binders targeting the transferrin receptor.
TRANSPEP® library consists of de novo peptides with diverse affinities and properties for multivalent fusion with a conventional antibody, ensuring optimized avidity control.
Library
TRANSPEP®
We harness the synergy of de novo design, structural biology, and directed evolution approaches to craft hypercompact and stable protein binders targeting the transferrin receptor.
TRANSPEP® library consists of de novo peptides with diverse affinities and properties for multivalent fusion with a conventional antibody, ensuring optimized avidity control.
Brain Vessels
Reticulocytes
Super-Selective Binding
TRANSMAB® antibodies selectively bind to the dense clustering of transferrin receptor (TfR) on brain vessels, while avoiding other TfR-expressing tissues, such as immature red blood cells, which have a relatively low surface receptor concentration.
Brain Vessels
Reticulocytes
Super-Selective Binding
TRANSMAB® antibodies selectively bind to the dense clustering of transferrin receptor (TfR) on brain vessels, while avoiding other TfR-expressing tissues, such as immature red blood cells, which have a relatively low surface receptor concentration.
Brain Vessels
Reticulocytes
Super-Selective Binding
TRANSMAB® antibodies selectively bind to the dense clustering of transferrin receptor (TfR) on brain vessels, while avoiding other TfR-expressing tissues, such as immature red blood cells, which have a relatively low surface receptor concentration.
Superior Brain Penetration
TRANSMAB® leverages TfR, which is densely present on brain microvessels throughout the entire brain – a common feature across difference species, including humans. This makes TRANSMAB® an ideal strategy for developing therapeutic antibodies targeting brain diseases.
Key properties of TRANSMAB® include:
High brain bioavailability
Brain-selective biodistribution
Unaltered systemic pharmacokinetics
No TfR-related side effects
Cross-species reactivity
Superior Brain Penetration
TRANSMAB® leverages TfR, which is densely present on brain microvessels throughout the entire brain – a common feature across difference species, including humans. This makes TRANSMAB® an ideal strategy for developing therapeutic antibodies targeting brain diseases.
Key properties of TRANSMAB® include:
High brain bioavailability
Brain-selective biodistribution
Unaltered systemic pharmacokinetics
No TfR-related side effects
Cross-species reactivity
Superior Brain Penetration
TRANSMAB® leverages TfR, which is densely present on brain microvessels throughout the entire brain – a common feature across difference species, including humans. This makes TRANSMAB® an ideal strategy for developing therapeutic antibodies targeting brain diseases.
Key properties of TRANSMAB® include:
High brain bioavailability
Brain-selective biodistribution
Unaltered systemic pharmacokinetics
No TfR-related side effects
Cross-species reactivity